Perimenopause: Open Controversies Every Woman Deserves to Know About

Why Perimenopause Is Still Scientifically Contested

The menopause transition affects every woman who lives long enough, yet the medical evidence base for what happens during those years, and what to do about it, remains genuinely disputed. That is not a reason to panic. It is a reason to understand the debates so you can ask sharper questions at your next appointment.

Perimenopause begins with the first signs of irregular cycles or hormonal fluctuation and ends 12 months after the final menstrual period. The Menopause Society (formerly NAMS) defines its stages using the STRAW+10 criteria, which divide the transition into early and late phases based on cycle length changes and FSH levels. Even this foundational staging system, published in its current form in 2012, has its critics, because it was built largely from data on women who were already postmenopausal when enrolled in studies.

The body of perimenopausal research is thinner than most women realize. Many of the most-cited trials enrolled postmenopausal women. Extrapolating those results backward to the transition years is a core source of ongoing controversy.

Controversy 1: Can Perimenopause Actually Be Diagnosed with a Blood Test?

The short answer is: not reliably, and clinicians are not fully in agreement about what to do with that reality.

FSH, estradiol, and anti-Müllerian hormone (AMH) are the most commonly ordered markers. Each has real limitations during the transition years.

FSH Fluctuates Too Much to Be Definitive

FSH rises as ovarian reserve declines, but during early perimenopause it swings dramatically from cycle to cycle. A single elevated FSH (often cited as >25-40 IU/L depending on the lab) can appear in a woman who ovulates normally the following month. A 2012 analysis in Menopause confirmed that FSH variability in the early transition is high enough to make a single reading diagnostically unreliable. ACOG and The Menopause Society both state that in women over 45 with typical symptoms, the clinical picture alone is sufficient for diagnosis, and routine hormone testing adds little.

AMH: A Better Marker, Still Imperfect

AMH, produced by small antral follicles, declines more steadily than FSH and may better predict the final menstrual period. A 2017 study in the Journal of Clinical Endocrinology and Metabolism found that very low AMH (<0.10 ng/mL) was associated with menopause within 5 years in women over 42. The controversy: AMH assays are not standardized across labs, insurance rarely covers them for this indication, and no professional society has endorsed AMH as a routine perimenopausal diagnostic tool.

What This Means for You

If you are 45 or older with irregular cycles and vasomotor symptoms, most guidelines say a blood test is unnecessary to start a clinical conversation about treatment. If you are younger than 45, testing matters more, because premature ovarian insufficiency (POI) requires a different management approach. ACOG Practice Bulletin No. 141 recommends testing with FSH on two occasions at least 4-6 weeks apart in women under 40 suspected of POI.

Controversy 2: The Timing Hypothesis for Hormone Therapy

No controversy in menopause medicine has generated more confusion, or more harm, than the question of when to start hormone therapy and whether it is safe at all.

The WHI Study and Its Aftermath

The Women's Health Initiative (WHI) 2002 publication reported increased risks of breast cancer, stroke, and cardiovascular events in women taking conjugated equine estrogen plus medroxyprogesterone acetate. The initial findings triggered a more than 50% drop in hormone therapy prescriptions in the United States. Women stopped therapy. Doctors became reluctant to prescribe. That narrative is now understood to be incomplete.

The WHI enrolled women with a mean age of 63, most of whom were more than 10 years past menopause. Applying those results to a 47-year-old in early perimenopause is the central flaw critics have identified for over two decades.

What the Timing Hypothesis Actually Says

The "timing hypothesis" or "window of opportunity" concept holds that estrogen therapy started close to menopause, within roughly 10 years or before age 60, may reduce cardiovascular risk rather than increase it. A reanalysis of WHI data by age subgroup, published in JAMA in 2007, showed that women aged 50-59 who took estrogen-only therapy had a non-significant trend toward fewer coronary events compared with placebo. The ELITE trial (Early versus Late Intervention Trial with Estradiol), published in the New England Journal of Medicine in 2016, found that oral estradiol slowed the progression of carotid intima-media thickness in recently postmenopausal women but not in those who started therapy more than 10 years after menopause. This is the most direct prospective evidence for the timing window to date.

What Remains Genuinely Unresolved

The timing hypothesis has not been tested in a large randomized trial specifically enrolling perimenopausal women. The KEEPS trial (Kronos Early Estrogen Prevention Study) randomized women within 3 years of menopause and found no significant difference in CIMT between estrogen and placebo groups at 4 years, though a secondary KEEPS-Cognitive Health analysis found that oral conjugated equine estrogen was associated with worse verbal memory compared with placebo, while transdermal estradiol was not. That cognitive signal remains controversial and not yet replicated at scale.

The Menopause Society's 2023 position statement states that for women under 60 or within 10 years of menopause without contraindications, the benefits of MHT for symptom management generally outweigh the risks. The European Menopause and Andropause Society and the British Menopause Society hold similar positions. This is the current best-available guidance, not a settled scientific consensus.

Controversy 3: Testosterone for Women in the Menopause Transition

Testosterone is the most prescribed hormone you have probably never been told about clearly. And the controversy around it is real.

The Case For

Testosterone declines throughout women's reproductive years, not abruptly at menopause. By the late perimenopause, levels are roughly half of what they were at age 20. A 2019 systematic review and meta-analysis in the Lancet Diabetes and Endocrinology, covering 36 randomized controlled trials and more than 8,000 women, found that testosterone significantly improved sexual function, including desire, arousal, and orgasm, compared with placebo or comparator. This is the strongest evidence testosterone has for any indication in women.

The Case Against (or at Least, the Caution)

No systemic testosterone product is FDA-approved for women in the United States. Every formulation used clinically, testosterone cypionate injections, compounded creams, pellets, or male-dose patches cut to size, is off-label. The doses used in the Lancet meta-analysis aimed for premenopausal physiological levels. Supraphysiological dosing, which can occur with pellets especially, carries risks of acne, hair loss, clitoral enlargement, and voice changes that may not fully reverse.

Long-term safety data beyond 2 years in women is thin. A 2023 joint position statement from The Menopause Society, the International Society for the Study of Women's Sexual Health, and the British Menopause Society recommends testosterone for hypoactive sexual desire disorder (HSDD) in postmenopausal women, with transdermal delivery preferred, and explicitly states that data in premenopausal and perimenopausal women are insufficient to make a recommendation. Breast cancer safety data is reassuring in the short term but not long-term established.

A Practical Framework for Thinking About Testosterone in Perimenopause

Three questions help organize the decision clinically:

1. Is the primary complaint sexual desire, function, or both? If yes, testosterone has the best evidence.
2. Is the woman's total testosterone already in the lower normal premenopausal range? Supplementing into supraphysiological territory adds risk without added benefit.
3. Is she using reliable contraception? Testosterone is classified as FDA Pregnancy Category X in its male-dose formulations and is teratogenic, particularly to a female fetus. This matters in perimenopause because ovulation still occurs.

Controversy 4: Perimenopause, Depression, and the Psychiatric Misdiagnosis Problem

This is the controversy that has the most direct impact on women's mental health right now.

The Evidence That Perimenopause Is a Vulnerable Window

The SWAN (Study of Women's Health Across the Nation) study, an ongoing longitudinal cohort that has followed over 3,300 women across racial and ethnic groups since 1996, found that the risk of a high Center for Epidemiological Studies-Depression score was approximately twice as high during perimenopause as during premenopause, even after controlling for prior depression and life events. This is not simply life stress. Fluctuating estradiol appears to sensitize certain women's limbic systems to mood disruption in a way that stabilizes after the final menstrual period.

A landmark 2006 study by Schmidt et al. In the Archives of General Psychiatry demonstrated that perimenopausal women with no prior psychiatric history were two to four times more likely to develop a major depressive episode than premenopausal women. These women were not simply "stressed." They had a biological vulnerability tied directly to the hormonal transition.

Why Misdiagnosis Happens

The problem is structural. Primary care and even some psychiatry training programs have historically not taught perimenopause as a mood risk window. Women presenting with irritability, sleep disruption, concentration problems, and low motivation during their mid-to-late 40s are frequently started on SSRIs without a menopause history being taken.

SSRIs and SNRIs do have evidence for perimenopausal depression and even hot flashes. Escitalopram and desvenlafaxine have RCT data for vasomotor symptom reduction. But prescribing an antidepressant without first asking whether the woman is in perimenopause means missing the option of hormone therapy, which for hormonally-driven mood symptoms may be more directly targeted.

The 2023 Menopause Society position statement explicitly states that estrogen therapy is an effective treatment for perimenopausal depressive symptoms and may be preferable to antidepressants in women whose mood symptoms are clearly tied to the hormonal transition. That recommendation is not yet standard practice in most primary care offices.

Across Life Stages

Women with a history of premenstrual dysphoric disorder (PMDD) or postpartum depression appear to be at higher risk for perimenopausal mood disruption, suggesting a shared biology of sensitivity to hormonal flux rather than a single discrete episode.

Controversy 5: Cognitive Symptoms and the "Brain Fog" Debate

Many perimenopausal women report difficulty with word retrieval, concentration, and short-term memory. Whether this represents true neurological change, a reversible hormonal effect, or a downstream consequence of poor sleep remains actively debated.

What the SWAN Data Showed on Cognition

SWAN's longitudinal cognitive data found that perimenopausal women had modestly lower scores on tests of processing speed and verbal memory compared with their own premenopausal baselines. The good news from that same data: scores largely recovered in postmenopause. This suggests the cognitive complaints most women experience are real but typically transient, not a harbinger of dementia.

The Alzheimer's Risk Debate

A more contested question is whether estrogen loss at menopause contributes to longer-term Alzheimer's disease risk. Women account for approximately two thirds of all Alzheimer's diagnoses in the United States, a disparity that cannot be fully explained by longevity alone. Some researchers argue that estrogen's neuroprotective effects mean that early menopause or prolonged low-estrogen states increase risk. Others counter that the WHI Memory Study found that conjugated estrogen plus progestin increased dementia risk in women over 65, though again the timing issue applies: these were older, postmenopausal women, not perimenopausal women starting therapy early.

A 2023 review in JAMA Neurology concluded that the relationship between menopause timing, hormone therapy, and Alzheimer's risk remains underdetermined and that the timing of any potential intervention matters enormously. No major society currently recommends MHT for dementia prevention.

Controversy 6: Sleep Disruption and Whether It's Primary or Secondary

Perimenopausal women report sleep problems at rates far higher than age-matched men. The controversy: how much of this is driven directly by hormonal change versus hot flashes interrupting sleep versus primary sleep disorders like obstructive sleep apnea (OSA) that go undiagnosed?

OSA Is Underdiagnosed in Women, Particularly at Menopause

A large epidemiological study in the American Journal of Respiratory and Critical Care Medicine found that postmenopausal women had a risk of OSA comparable to age-matched men, while premenopausal women had significantly lower rates. Progesterone is thought to be a respiratory stimulant, so its loss at menopause may unmask OSA.

Women with OSA are less likely to report the classic symptom of loud snoring and more likely to report insomnia, fatigue, and mood disturbance. These are also the symptoms attributed to perimenopause itself. The result: many women are prescribed sleep aids or hormone therapy when they need a sleep study. The American Academy of Sleep Medicine recommends clinical suspicion for OSA in any perimenopausal woman with refractory insomnia.

The Evidence Gap Explicitly Named

Women have been historically underrepresented in sleep disorder research. Most foundational OSA studies enrolled predominantly male cohorts. The SWAN Sleep Study has helped, but longitudinal sleep data in perimenopausal women spanning the full transition remains limited. When your clinician says "this is just perimenopause," that is sometimes accurate, and sometimes an evidence gap being papered over.

Controversy 7: Race, Ethnicity, and the Data Representation Problem

The SWAN study is, by design, multiracial and multiethnic, including Black, white, Hispanic, Japanese-American, and Chinese-American women. Its data has shown that Black women experience hot flashes that are more frequent, longer in duration, and more distressing than those of white women, and begin them earlier in the transition. Hispanic and Black women also report more sleep disturbance.

Yet the WHI, the ELITE trial, and most hormone therapy trials remain predominantly white. Extrapolating safety and efficacy data to Black and Hispanic women involves real assumptions. Treatment guidelines rarely acknowledge this explicitly. A 2021 commentary in Menopause by Crandall et al. Called directly for disaggregated racial and ethnic data in future menopause trials, noting that symptom burden, cardiovascular risk profiles, and health-care access differ substantially across groups. This is an evidence gap with real clinical consequences today.

Contraception During Perimenopause: A Misunderstood Necessity

Perimenopause is not infertility. Ovulation continues intermittently throughout the transition, and unintended pregnancy rates in women aged 40-44 remain clinically significant. The CDC U.S. Medical Eligibility Criteria for Contraceptive Use advises that women should continue using contraception until 12 consecutive months of amenorrhea confirm menopause.

This intersects with controversy in two ways.

First, some hormonal contraceptives, particularly combined oral contraceptives, may mask perimenopausal symptoms and make it hard to know where a woman is in the transition. FSH drawn during the pill-free interval is unreliable. The clinical implication: if you want to assess your hormonal status while using hormonal contraception, a provider-supervised hormone holiday of at least 6-8 weeks may be needed.

Second, if a perimenopausal woman is using testosterone off-label (see Controversy 3), contraception is not optional. Testosterone is teratogenic, and because ovulation is unpredictable, a reliable non-hormonal method (copper IUD) or a progestin-only method (hormonal IUD, implant) should be in place. The LNG-IUS (levonorgestrel intrauterine system) provides both contraception and endometrial protection if systemic estrogen is being used, making it a practical dual-purpose option per ACOG guidance.

Pregnancy after the late-40s carries elevated risks of chromosomal abnormalities, gestational diabetes, preeclampsia, and cesarean delivery. Lactation is physiologically possible after an unintended perimenopausal pregnancy, and estrogen-containing contraceptives should be avoided until breastfeeding is established, as they can suppress milk supply. Progestin-only or copper IUD options are preferred in this scenario.

Who Is Most Affected by These Controversies in Practice

Not every woman experiences these debates equally. Women who are most likely to be underserved by the current evidence gaps include:

• Women in their early 40s with symptoms who are told they are "too young" for perimenopause.
• Black and Hispanic women whose more severe symptom burden is not reflected in most guideline evidence.
• Women with PCOS, whose already-irregular cycles make cycle-based staging nearly impossible, and whose testosterone levels and metabolic profiles complicate standard hormone decisions.
• Women with a history of breast cancer, for whom MHT remains a major unsettled question and for whom non-hormonal options (SSRIs, SNRIs, gabapentin, oxybutynin, fezolinetant) are the current standard but have their own evidence gaps in this population.
• Women with premature ovarian insufficiency (POI), whose estrogen deficiency begins years earlier and for whom the WHI data is particularly irrelevant yet still sometimes cited as a reason to withhold therapy.

As WomanRx reviewer Rachel Goldberg, MD, notes: "The most common clinical error I see is applying WHI data, collected in women averaging 63 years old, to a 46-year-old in perimenopause with hot flashes and insomnia. These are not the same population. The evidence gap is real, but it does not mean doing nothing."

A Note on Emerging Research to Watch

Several ongoing and recently completed studies are likely to change parts of this picture over the next 5 years:

The WHISCA follow-up studies are extending the cognitive data from the WHI. The REPLENISH trial evaluated transdermal progesterone specifically, addressing whether progestogen type changes risk profiles differently. The Menopause Research Society has called for new perimenopausal-specific RCTs that enroll women in the STRAW+10 early transition stage, not postmenopausal women, as the comparator group.

Fezolinetant (Veozah), FDA-approved in May 2023 as a non-hormonal neurokinin B receptor antagonist for vasomotor symptoms, represents the first new mechanistic class for perimenopausal symptoms in decades. Its place in the hierarchy of treatment options compared with MHT is not yet settled, and it has not been studied in women who are still having periods.

The field is moving. The controversies above are not permanent. But they are real, active, and affecting women's care today.